X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Nurix currently intends to use the net proceeds to fund clinical development of its drug candidates, including NX-5948, an investigational, orally bioavailable, small molecule degrader of BTK, for the treatment of B-cell malignancies.
Lead Product(s): NX-5948
Therapeutic Area: Oncology Product Name: NX-5948
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: J.P. Morgan Securities
Deal Size: $175.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering April 11, 2024
Details:
Nurix and Sanofi have agreed to extend the research period for the ongoing STAT6 degrader program, aimed at developing candidates for treating inflammation and autoimmune diseases.
Lead Product(s): Undisclosed
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Small molecule
Partner/Sponsor/Collaborator: Sanofi
Deal Size: $2,577.0 million Upfront Cash: $55.0 million
Deal Type: Expanded Collaboration April 09, 2024
Details:
NX-5948 is an orally available, selective degrader of Bruton’s tyrosine kinase. Currently, it is being evaluated with patients for the treatment of B cell malignancies.
Lead Product(s): NX-5948
Therapeutic Area: Oncology Product Name: NX-5948
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 09, 2024
Details:
The collaboration aims to support the clinical development of GS-6791 (NX-0479), a potent, selective, oral IRAK4 degrader that has potential applications in the treatment of rheumatoid arthritis and other inflammatory diseases
Lead Product(s): NX-0479
Therapeutic Area: Immunology Product Name: GS-6791
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Gilead Sciences
Deal Size: $1,903.5 million Upfront Cash: $45.0 million
Deal Type: Collaboration April 02, 2024
Details:
NX-2127 is a novel bifunctional molecule that degrades BTK and cereblon neosubstrates Ikaros (IKZF1) and Aiolos (IKZF3). NX-2127 is currently being evaluated in a Phase 1 clinical trial in patients with relapsed or refractory B cell malignancies.
Lead Product(s): NX-2127
Therapeutic Area: Oncology Product Name: NX-2127
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 11, 2024
Details:
NX-5948 is an investigational, orally bioavailable, small molecule degrader of BTK. It is currently being evaluated in a Phase 1 clinical trial in patients with relapsed or refractory B cell malignancies.
Lead Product(s): NX-5948
Therapeutic Area: Oncology Product Name: NX-5948
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 16, 2024
Details:
NX-2127 is a novel bifunctional molecule that degrades BTK and cereblon neosubstrates Ikaros (IKZF1) and Aiolos (IKZF3). NX-2127 is currently being evaluated in a Phase 1 clinical trial in patients with relapsed or refractory B cell malignancies.
Lead Product(s): NX-2127
Therapeutic Area: Oncology Product Name: NX-2127
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 01, 2023
Details:
The collaboration aims to advance a new class of medicines called Degrader-Antibody Conjugates (DACs) for use in cancer and will focus on an innovative approach to combine two powerful technologies to target cancer ADC and targeted protein degradation (TPD).
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Seagen
Deal Size: $3,460.0 million Upfront Cash: $60.0 million
Deal Type: Collaboration September 07, 2023
Details:
Under the terms of the agreement, Gilead has licensed Nurix’s investigational GS-6791 (NX-0479), an oral IRAK4 degrader that targets both the scaffold and kinase functions of the protein kinase to block inflammatory responses downstream of TLR and the pro-inflammatory IL1Rs.
Lead Product(s): NX‑0479
Therapeutic Area: Immunology Product Name: GS-6791
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Gilead Sciences
Deal Size: $445.0 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement March 20, 2023
Details:
NX-5948 is an investigational, orally bioavailable, small molecule degrader of BTK. NX-5948 has been designed to lack cereblon immunomodulatory activity for potential applications in indications where sparing immunomodulatory activity may be beneficial.
Lead Product(s): NX-5948
Therapeutic Area: Oncology Product Name: NX-5948
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 15, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
